Your data. DELIVERED.

Full-service preclinical CRO specialized in oncology and musculoskeletal disease models

What type of preclinical expertise are you seeking today?

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Welcome to
Pharmatest

Pharmatest offers preclinical in vitro assays, in vivo efficacy models and ex vivo bone analysis services in the fields of oncology and musculoskeletal diseases.

We are the leading experts in combining cancer and bone biology having special expertise in bone metastases. Our cancer models cover comprehensive portfolio of xenograft, syngeneic and immuno-oncology models. We have substantial experience in performing studies with targeted radionuclide therapy in both, in vitro and in vivo studies.

Our models of musculoskeletal include osteoclast and osteoblast in vitro studies and animal models of osteoporosis, osteoarthritis and rare bone disease.

Ex vivo services cover complete histomorphometry and non-invasive imaging for bone and soft tissue and large panel of biomarkers for preclinical and clinical samples. Via our large collaboration network, we can also offer GLP-toxicology studies for you.

Pharmatest provides clinically predictive preclinical models specifically engineered to decrease the high failure rates typically encountered during clinical trials. 

With a 25+ year track record and thousands of compounds tested, our specialists utilize state-of-the-art laboratories to deliver high-quality in vitro and in vivo efficacy data. We offer the deep scientific knowledge required to select or customize the precise oncology and musculoskeletal disease models needed to advance your drug candidates with confidence. 

What can we do for You? Request a Quote!

Cancer models

Pharmatest is a CRO specialized in orthotopic and metastasis models, and as bone experts we have special expertise in bone metastasis models.

Skeletal disease models

Pharmatest offers full-service efficacy testing of new drug candidates for treatment of osteoporosis and osteoarthritis.

Bone analysis

Pharmatest’s standard study setups in different disease models include different combinations of the bone analysis methods that can also be used as stand-alone services.

Clinical biomarkers

Pharmatest provides full-service re­search solutions for fast and reliable measure­ment of biomarkers in clinical (human) samples.

Radiopharmaceuticals testing

Pharmatest has performed a large amount of studies and acquired special expertise in testing α-emitters such as Ra-223, Ra-224 and Th-227.

Cancer models

Pharmatest is a CRO specialized in orthotopic and metastasis models, and as bone experts we have special expertise in bone metastasis models.

Musculoskeletal disease models

Pharmatest offers full-service efficacy testing of new drug candidates for treatment of osteoporosis and osteoarthritis.

Bone analysis

Pharmatest’s standard study setups in different disease models include different combinations of the bone analysis methods that can also be used as stand-alone services.

Clinical biomarkers

Pharmatest provides full-service re­search solutions for fast and reliable measure­ment of biomarkers in clinical (human) samples.

Radiopharmaceuticals testing

Pharmatest has performed a large amount of studies and acquired special expertise in testing α-emitters such as Ra-223, Ra-224 and Th-227.

News

BIO-Europe Spring 2026

Pharmatest participated BIO‑EUROPE Spring in Lisbon, Portugal, March 23–25, 2026. The conference brought together the companies of the bio industry for

Read more »
30/03/2026

Conferences 2026

In 2026, our team will be on the road connecting with the global scientific community across oncology and musculoskeletal research.

Read more »
12/02/2026

Testimonials

Dr. Karl ZiegelbauerSVP Therapeutic Research Groups, Pharmaceuticals Division, Bayer Pharma AG, Germany
"Bayer has worked for several years with Pharmatest and we are very impressed about the high quality of the work they have done for us."
Dr. Hubert ChenChief Medical Officer, Pfenex Inc., USA
“It was a great pleasure working with Pharmatest. The scientific expertise and advice offered by the Pharmatest team were top notch. There was excellent, proactive communication from the very beginning of the project, which finished on time and within budget. I have no hesitations in recommending Pharmatest as a high-quality CRO for preclinical services in skeletal diseases.”
Dr. Dana T. AftabExecutive Vice President, Business Operations, Exelixis Inc., USA
"Exelixis has been working with Pharmatest since 2011, and we have been very pleased with their excellent data quality, detailed and thorough reports, and highly professional and knowledgeable staff.”
Dr. Satu VainikkaCEO, Valirx Plc, UK
"Pharmatest has been our preferred supplier of preclinical proof-of-concept studies for some time now and we are very satisfied about the high quality and scientific expertise that they provide."
Dr. Leslie HolsingerVice President of Biology, Virobay Inc., USA
"Virobay has worked with Pharmatest on both in vitro and in vivo model analysis of drug candidates and we are very pleased with the excellent quality of their work and the high level of scientific expertise they provide to our studies.”
Hanne Heidenheim BakM.Sc. Pharm, Senior Project Director, Head of Project Management, Zealand Pharma A/S, Denmark
"It has been a pleasure working with the Pharmatest team. You have been an excellent communicator, always informing us promptly on changes or questions that have come up and providing great feedback to our questions. We certainly experience Pharmatest as a very competent company with very professional employees."
Dr. Pekka KallioHead of Oncology Research, Orion Oyj, Finland
“Orion started to use services of Pharmatest more than 10 years ago, and we are happy about the excellent scientific quality of their work and reporting.”
Dr. Jean-Baptiste MarchandHead of Proteins Science Group, Transgene, France
”Transgene and Pharmatest have successfully collaborated since 2009 for the in vitro and in vivo preclinical evaluation of TG’s monoclonal platform in different skeletal diseases. Transgene was particularly impressed by the high professionalism of Pharmatest’s scientist staff, who participated actively nearby our teams in the designs, execution and analysis of the experiments.”
Dr. Nick FlinnHead of Pre-clinical Development, Amura Therapeutics, England
"Amura has worked closely with Pharmatest for over a decade in the areas of bone turnover and bone metastases. Pharmatest has provided support and advice in addition to a first class in vitro and in vivo screening service for the analysis and progression of Amura's drug candidates. We are always impressed with the excellent quality of their work and the high level of scientific expertise they provide to our studies.”